undamentalytics Newsletter
Sign in

Syndax Pharmaceuticals Inc balance sheet

At the end of fiscal 2025, Syndax Pharmaceuticals Inc had total assets of $530m, total liabilities of $465m and shareholders' equity of $64.6m. It held $135m in cash against $350m of debt: net debt of $215m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents232435342511522274295154135136
Receivables————————083847
Inventory————————003339
Total current assets881091338362299448490581603528567
Total assets901091378464301450497613725530693
Accounts payable122164641012174
Deferred revenue (current)112222——————
Total current liabilities51016161819212958104120121
Short-term debt————————0344344344
Long-term debt————————03320244
Total debt000002020200675350594
Total liabilities232533313248413059437465710
Shareholders' equity−25284104533225240846755428865−17
Non-controlling interests and other (assets − liabilities − equity)319———————————
Net debt (negative = net cash)−23−24−35−34−25−95−202−54−295521215458
Shares outstanding—18m24m25m27m48m55m—85m86m87m90m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: PTGX vs SNDXSNDX vs VIRPHAT vs SNDX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Syndax Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Syndax Pharmaceuticals Inc.